Molecule Details
| InChIKey | PMJIHLSCWIDGMD-UHFFFAOYSA-N |
|---|---|
| Compound Name | Tideglusib |
| Canonical SMILES | O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 4 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 6.46 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB12129 |
|---|---|
| Drug Name | Tideglusib |
| CAS Number | 865854-05-3 |
| Groups | approved investigational withdrawn |
| ATC Codes | nan |
| Description | Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).[A31601] Tideglusi... |
Categories: Glycogen Synthase Kinase 3, antagonists & inhibitors Sulfur Compounds Thiazoles
Cross-references: BindingDB: 50166940 ChEBI: 147398 CHEMBL3545157 ChemSpider: 9488589 PubChem:11313622 PubChem:347828428 Wikipedia: Tideglusib ZINC: ZINC000013985228
Target Activities (4)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| P49841 | GSK3B | Homo sapiens | Human | PF00069 | 7.1 | IC50 | ChEMBL;BindingDB |
| Q9UBN7 | HDAC6 | Homo sapiens | Human | PF00850 PF02148 | 6.0 | IC50 | ChEMBL |
| P0DTD1 | rep | Severe acute respiratory syndrome coronavirus 2 | Pathogen | PF13087 PF16251 PF11501 PF12379 PF12124 PF11633 PF06471 PF06460 PF09401 PF20631 PF20633 PF20632 PF19215 PF19216 PF19219 PF19211 PF19218 PF16348 PF19217 PF19213 PF08716 PF08717 PF08710 PF08715 PF06478 PF01661 PF05409 PF00680 | 6.5 | IC50 | ChEMBL;BindingDB |
| Q9S446 | srtA | Staphylococcus aureus | Pathogen | PF04203 | 6.2 | IC50 | ChEMBL;BindingDB |
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P49841 | GSK3B | Glycogen synthase kinase-3 beta | antagonist | targets |